Erythema Chronicum Migrans
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
Glossitis, Benign Migratory
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
Melanocytic nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
PAL-M1 and PAL-M2 may be immunohistochemical markers for tumor progression in melanocytic proliferations.
|
3891875 |
1985 |
Dysplastic Nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
Influenza
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the sequence had a high degree of similarity to the peptidoglycan-associated outer membrane lipoprotein P6 of Haemophilus influenzae and the peptidoglycan-associated lipoprotein PAL of E. coli.
|
8576327 |
1995 |
Myofibromatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunocytochemistry (Ulex, factor VIII, JC/70A [CD31], PAL-E, BMA120, EN4, QBEnd10 [CD34], SMS actin) and ultrastructural studies showed no (marked) differences between different types of IMF.
|
8600777 |
1995 |
Infantile myofibromatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunocytochemistry (Ulex, factor VIII, JC/70A [CD31], PAL-E, BMA120, EN4, QBEnd10 [CD34], SMS actin) and ultrastructural studies showed no (marked) differences between different types of IMF.
|
8600777 |
1995 |
Hyperphenylalaninaemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We describe (i) an efficient recombinant approach to produce PAL enzyme, (ii) testing of PAL in orthologous N-ethyl-N'-nitrosourea (ENU) mutant mouse strains with HPA, and (iii) proofs of principle (PAL reduces HPA)-both pharmacologic (with a clear dose-response effect vs. HPA after PAL injection) and physiologic (protected enteral PAL is significantly effective vs. HPA).
|
10051643 |
1999 |
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR-2 expressing stromal blood vessels, also positive for the vascular endothelial marker PAL-E and the basement membrane marker laminin, were more abundant in RA and AS than in controls.
|
11824969 |
2002 |
Ankylosing spondylitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR-2 expressing stromal blood vessels, also positive for the vascular endothelial marker PAL-E and the basement membrane marker laminin, were more abundant in RA and AS than in controls.
|
11824969 |
2002 |
Hemangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By contrast, blood vessel endothelium and hemangiomas were strongly positive for PAL-E and CD34 but were mostly negative for CD9 and podoplanin.
|
14559986 |
2003 |
Lymphangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regular lymphatic endothelium and lymphangiomas were strongly positive for CD9 and podoplanin but were mostly negative for PAL-E and CD34.
|
14559986 |
2003 |
Neoplasms, Vascular Tissue
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Using immunohistochemistry, expression of CD9 was studied in 17 samples of head and neck mucosa and skin (laryngeal mucosa: n = 2, oral: n = 6, and epidermis: n = 9) and a variety of vascular tumors (lymphangiomas: n = 9, juvenile nasopharyngeal angiofibromas: n = 4, hemangiomas: n = 7, angiosarcomas: n = 5, and Kaposi's sarcomas: n = 7) and compared with the expression of CD34 and PAL-E (blood vessel markers) and the lymphatic marker podoplanin.
|
14559986 |
2003 |
Kaposi Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemistry, expression of CD9 was studied in 17 samples of head and neck mucosa and skin (laryngeal mucosa: n = 2, oral: n = 6, and epidermis: n = 9) and a variety of vascular tumors (lymphangiomas: n = 9, juvenile nasopharyngeal angiofibromas: n = 4, hemangiomas: n = 7, angiosarcomas: n = 5, and Kaposi's sarcomas: n = 7) and compared with the expression of CD34 and PAL-E (blood vessel markers) and the lymphatic marker podoplanin.
|
14559986 |
2003 |
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We also discuss the possible involvement of the PAL-mechanism in carcinogenesis.
|
15970690 |
2005 |
Systemic Scleroderma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Daily physical activities (243 ± 145 min per day vs 397 ± 142 min, respectively; P = 0.005) and PAL were significantly reduced in SSc compared with controls (1.5 ± 0.4 vs 2 ± 0.7, respectively; P = 0.019).
|
25832135 |
2017 |
Motor Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The results demonstrated that chronic treatment with D-Ala2-GIP-glu-PAL inhibits MPTP -induced Parkinsonism-like motor disorders in mice, and that the drug prevents dopaminergic neuronal loss in the substantia nigra pars compacta (SNpc).
|
27913104 |
2017 |
Mild cognitive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The CANTAB-PAL discriminated only between HC and MCI, possibly because of reduced statistical power.
|
28106560 |
2017 |
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
A lectin with strong cytotoxic effect on human colon cancer HT29 and monkey kidney VERO cells was recently identified from the Australian indigenous mushroom Psathyrella asperospora and named PAL.
|
28168856 |
2017 |
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A lectin with strong cytotoxic effect on human colon cancer HT29 and monkey kidney VERO cells was recently identified from the Australian indigenous mushroom Psathyrella asperospora and named PAL.
|
28168856 |
2017 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |